FIELD: medicine. SUBSTANCE: method involves applying thymogen (L-glutamyl-L-triptophane) as diabetes therapy means. EFFECT: enhanced effectiveness of treatment; increased hypoglycemic insulin action; reduced lipid peroxidation level; beta-cells protection. 7 tbl
| Title | Year | Author | Number | 
|---|---|---|---|
| ANTIDIABETIC AGENT | 2001 | 
 | RU2197259C1 | 
| ANTIDIABETIC AGENT | 2001 | 
 | RU2195300C1 | 
| MEANS WITH HYPOGLYCEMIC, HYPOLIPIDEMIC AND ENERGY PROTECTIVE EFFECTS | 2016 | 
 | RU2630576C1 | 
| COMPOSITION POSSESSING ANTIDIABETIC ACTION | 2015 | 
 | RU2611353C2 | 
| ANTIDIABETIC COMPOSITION | 2009 | 
 | RU2430735C1 | 
| MEDICATION AND METHOD OF COMPLEX THERAPY OF PATIENTS WITH DIABETES MELLITUS | 2012 | 
 | RU2548731C2 | 
| ANTIDIABETIC AGENT | 1998 | 
 | RU2150952C1 | 
| TETRAPEPTIDE REGULATING GLUCOSE LEVEL IN DIABETES MELLITUS, PHARMACOLOGICAL AGENT BASED ON THEREOF AND METHOD FOR ITS APPLYING | 2003 | 
 | RU2242241C1 | 
| SUBSTITUTED 4-{[4-(3,3-DIOXIDO-1,3-BENZOXATHIOL-6-YL)ARYLOXY]METHYL}PIPERIDINES AS GPR119 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR PRODUCING AND USING THEM | 2014 | 
 | RU2576037C1 | 
| METHOD FOR SIMULATING ALLOXAN DIABETES | 2013 | 
 | RU2534411C1 | 
Authors
Dates
2001-04-27—Published
2000-06-09—Filed